Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Chief Technical Officer | March 06, 2023 | March 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date March 06, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 268,854 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Sale · Disposed 690 · Balance 268,854 F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
F2: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 8, 2023 16:26 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 690 | $15.26 | $10,531.75 |
DisclosureSEC source: 0001567619-23-004668 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,854 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 19:03 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 15 | $16.52 | $247.80 |
DisclosureSEC source: 0001567619-23-004268 · doc1.xml · nonDerivative · entry 3 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,644 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 19:03 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,198 | $15.82 | $18,950.56 |
DisclosureSEC source: 0001567619-23-004268 · doc1.xml · nonDerivative · entry 2 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,659 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 18:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 39,500 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0001567619-23-004545 · doc1.xml · derivative · entry 2 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 Underlying: Common Stock · 39,500 shares Expires 2033-03-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 18:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 14,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004545 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,544 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 19:03 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 792 | $16.17 | $12,803.71 |
DisclosureSEC source: 0001567619-23-004268 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,857 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 19:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,197 | $25.41 | $55,835.44 |
DisclosureSEC source: 0001567619-22-013925 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,649 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $25.00 to $25.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 24,925 RSUs. F4 · balance_after: Reflects the adjusted total which includes the purchase of 1,617 shares under the Arcutis Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| April 21, 2022 Filed Apr 21, 2022 18:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 2,197 | $20.42 | $44,872.19 |
DisclosureSEC source: 0001567619-22-008817 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,229 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.125 to $20.925, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 24,925 RSUs. Read SEC document |
| March 07, 2022 Filed Mar 7, 2022 20:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 28 | $16.44 | $460.46 |
DisclosureSEC source: 0001567619-22-006492 · doc1.xml · nonDerivative · entry 3 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,426 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F4 · price: The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · balance_after: Includes 24,925 RSUs. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 20:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 828 | $16.86 | $13,959.33 |
DisclosureSEC source: 0001567619-22-006492 · doc1.xml · nonDerivative · entry 2 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,454 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F3 · price: The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 20:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 35,300 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001567619-22-006492 · doc1.xml · derivative · entry 4 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,300 Underlying: Common Stock · 35,300 shares Expires 2032-03-03 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 20:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006492 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,282 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 775 | $17.75 | $13,758.34 |
DisclosureSEC source: 0001567619-22-006229 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,982 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021. F2 · price: The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,004 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 976 shares on May 31, 2021 and 28 shares on November 30, 2021. F4 · balance_after: Includes 14,000 RSUs. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 15:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 28,800 | $0.00 Strike: $32.44 | $0.00 |
DisclosureSEC source: 0001567619-21-005731 · doc1.xml · derivative · entry 2 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,800 Underlying: Common Stock · 28,800 shares Expires 2031-03-03 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 15:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005731 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,753 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2022, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 16,250 RSUs. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:50 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 780 | $34.57 | $26,967.72 |
DisclosureSEC source: 0001567619-21-005542 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,253 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021. F2 · balance_after: Includes 6,750 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 18, 2020 Filed Feb 16, 2021 19:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004140 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,033 F1 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 15:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 15,000 | $30.00 | $450,000.00 |
DisclosureSEC source: 0001567619-20-021191 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,533 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F3 · balance_after: Includes 1,254 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 1,038 shares on May 31, 2020 and 216 shares on November 30, 2020. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 21:01 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 15,000 | $30.00 | $450,000.00 |
DisclosureSEC source: 0001567619-20-017382 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,279 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 21:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $27.61 | $0.00 |
DisclosureSEC source: 0001567619-20-005548 · doc1.xml · derivative · entry 4 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-02-27 F5 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 21:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005548 · doc1.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,279 F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024. Read SEC document |
| February 04, 2020 Filed Feb 4, 2020 18:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionSeries A Preferred Stock · Derivative | 24,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006595 · doc4.xml · derivative · entry 4 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
| February 04, 2020 Filed Feb 4, 2020 18:24 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | ConversionCommon Stock | 24,991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-006595 · doc4.xml · nonDerivative · entry 1 OSBORNE DAVID W · CIK 0001252999 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.